Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky

Charles A. Kunos, Denise Fabian, Dava W. Piecoro, Dana Napier, Rachel W. Miller, Frederick R. Ueland

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: High-risk human epidermal growth factor receptor 2 (HER2)-positive adenocarcinomas associate with early recurrence and death, prompting consideration of novel radiotherapeutic options like a trastuzumab-linked thorium-227 alpha-particle emitting radionuclide. Methods: We conducted a retrospective pilot biomarker study of uterine cervix cancers among patients in Appalachian Kentucky, to characterize an exploitable triage biomarker like HER2 expression before starting a prospective phase 0 trial. Results: Most (60%) adenocarcinomas showed HER2 cell-surface overexpression, whereas squamous cell carcinomas (4%) did not do so. Discussion: Further validation tests of HER2 expression as a triage biomarker for radiopharmaceutical selection are warranted.

Original languageEnglish
Article number948348
JournalFrontiers in Oncology
Volume13
DOIs
StatePublished - Jan 24 2023

Bibliographical note

Publisher Copyright:
Copyright © 2023 Kunos, Fabian, Piecoro, Napier, Miller and Ueland.

Keywords

  • HER2/neu
  • radiopharmaceutical
  • triage
  • uterine cervical adenocarcinoma
  • uterine cervical cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky'. Together they form a unique fingerprint.

Cite this